Considerations when commercial modelling a universal influenza vaccine. Published 4th August 2010.
Against the backdrop of a growing and rapidly evolving influenza vaccine market, two of the major manufacturers are now involved with the development of universal influenza vaccines. According to VacZine Analytics meeting the "ideal" vaccine profile could be the most valuable opportunity in the whole R&D pipeline.
PAGES: 2
PREMIUMThis article is available only on a "pay per view" basis or to purchasers of MarketVIEW: Universal influenza vaccines (CAT No: VAMV020)
